Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Revenue (2020 - 2023)

Inhibikase Therapeutics (IKT) has 4 years of Revenue data on record, last reported at $1.0 in Q4 2023.

  • On a quarterly basis, Revenue fell 100.0% to $1.0 in Q4 2023 year-over-year; TTM through Sep 2024 was $1.0, a 100.0% decrease, with the full-year FY2023 number at $260501.0, up 111.03% from a year prior.
  • Revenue reached $1.0 in Q4 2023 per IKT's latest filing, down from $79569.0 in the prior quarter.
  • Over the last five years, Revenue for IKT hit a ceiling of $1.4 million in Q1 2021 and a floor of $1.0 in Q4 2023.
  • A 4-year average of $261438.4 and a median of $72045.0 in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 3169.86% in 2022, then plummeted 100.0% in 2023.
  • Tracing IKT's Revenue over 4 years: stood at $170416.0 in 2020, then tumbled by 98.86% to $1944.0 in 2021, then soared by 3169.86% to $63566.0 in 2022, then tumbled by 100.0% to $1.0 in 2023.
  • Business Quant data shows Revenue for IKT at $1.0 in Q4 2023, $79569.0 in Q3 2023, and $116410.0 in Q2 2023.